Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1
Clinical trial NCT06354387 · COMPLETED
Trial details
- NCT number
- NCT06354387
- Sponsor
- China Medical University Hospital
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-16
- Primary completion
- 2026-02-28
- Enrollment
- 5
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.